Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility
Problem Many countries have limited experience of securing the best prices for drugs and have little negotiating power. This is particularly true for the complex, lengthy and expensive regimens used to treat multidrug-resistant tuberculosis. Approach The Stop TB Partnership's Global Drug Facili...
Saved in:
Main Authors: | Kaspars Lunte (Author), Thierry Cordier-Lassalle (Author), Joel Keravec (Author) |
---|---|
Format: | Book |
Published: |
The World Health Organization.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Global Drug Facility as an intervention in the market for tuberculosis drugs
by: Nimalan Arinaminpathy, et al.
Published: (2015) -
TUBERCULOSIS WITH MULTIDRUG-RESISTANT AND EXTENSIVELY DRUG-RESISTANT OF MICOBACTERIUM TUBERCULOSIS IN THE RUSSIAN FEDERATION
by: A.E. ERGESHOV, et al.
Published: (2018) -
ANTITUBERCULOSIS DRUG ALLERGY IN PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS
by: B.B. MAYKANAEV, et al.
Published: (2021) -
Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis
by: N. Yu. Nikolenko, et al.
Published: (2021) -
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024
by: Stefan Kohler, et al.
Published: (2024)